Book contents
- Multiparameter Flow Cytometry in the Diagnosis of Haematologic Malignancies
- Multiparameter Flow Cytometry in the Diagnosis of Haematologic Malignancies
- Copyright page
- Contents
- Contributors
- Preface
- Abbreviations
- Chapter 1 Flow Cytometry in Clinical Haematopathology
- Chapter 2 Antigens
- Chapter 3 Flow Cytometry of Normal Blood, Bone Marrow and Lymphatic Tissue
- Chapter 4 Reactive Conditions and Other Diseases Where Flow Cytometric Findings May Mimic Haematological Malignancies
- Chapter 5 Examples of Immunophenotypic Features in Various Categories of Acute Leukaemia
- Chapter 6 Acute Lymphoid Leukaemia and Minimal/Measurable Residual Disease
- Chapter 7 Immunophenotyping of Mature B-Cell Lymphomas
- Chapter 8 Plasma Cell Myeloma and Related Disorders
- Chapter 9 Mature T-Cell Neoplasms and Natural Killer-Cell Malignancies
- Chapter 10 Flow Cytometric Diagnosis of Classic Hodgkin Lymphoma in Lymph Nodes
- Chapter 11 Measurable Residual Disease in Acute Myeloid Leukaemia
- Chapter 12 Ambiguous Lineage and Mixed Phenotype Acute Leukaemia
- Chapter 13 Flow Cytometry in Myelodysplastic Syndromes
- Chapter 14 Future Applications of Flow Cytometry and Related Techniques
- Index
- References
Chapter 9 - Mature T-Cell Neoplasms and Natural Killer-Cell Malignancies
Published online by Cambridge University Press: 30 January 2025
By
Book contents
- Multiparameter Flow Cytometry in the Diagnosis of Haematologic Malignancies
- Multiparameter Flow Cytometry in the Diagnosis of Haematologic Malignancies
- Copyright page
- Contents
- Contributors
- Preface
- Abbreviations
- Chapter 1 Flow Cytometry in Clinical Haematopathology
- Chapter 2 Antigens
- Chapter 3 Flow Cytometry of Normal Blood, Bone Marrow and Lymphatic Tissue
- Chapter 4 Reactive Conditions and Other Diseases Where Flow Cytometric Findings May Mimic Haematological Malignancies
- Chapter 5 Examples of Immunophenotypic Features in Various Categories of Acute Leukaemia
- Chapter 6 Acute Lymphoid Leukaemia and Minimal/Measurable Residual Disease
- Chapter 7 Immunophenotyping of Mature B-Cell Lymphomas
- Chapter 8 Plasma Cell Myeloma and Related Disorders
- Chapter 9 Mature T-Cell Neoplasms and Natural Killer-Cell Malignancies
- Chapter 10 Flow Cytometric Diagnosis of Classic Hodgkin Lymphoma in Lymph Nodes
- Chapter 11 Measurable Residual Disease in Acute Myeloid Leukaemia
- Chapter 12 Ambiguous Lineage and Mixed Phenotype Acute Leukaemia
- Chapter 13 Flow Cytometry in Myelodysplastic Syndromes
- Chapter 14 Future Applications of Flow Cytometry and Related Techniques
- Index
- References
Summary
Mature T- and natural killer (NK)-cell neoplasms comprise multiple distinct disease entities. Diagnosis and classification of these entities require the integration of morphology, immunophenotype and cyto- and molecular genetics and correlation with clinical presentation. Multiparameter flow cytometry (MFC) is an important tool to immunophenotype T and NK cells. Our knowledge of the constellation of immunophenotypic aberrancies associated with certain disease entities has increased by the simultaneous analysis of more markers and molecular genetic studies. Genotype-phenotype associations have been identified contributing to a better understanding of the disease biology and clinical behaviour. T- and NK-cell disease entities in which MFC plays a central role in the diagnosis and classification are reviewed in this chapter. T-cell clonality analysis by MFC has become an assay used in many diagnostic laboratories. The availability of the JOVI-1 antibody against the T-cell receptor β constant region 1 protein (TRBC1) has greatly facilitated the detection of clonal TCRαβ T cells with high specificity and sensitivity. Despite the major advances in the diagnostic flow cytometry assays for the detection of T- and NK-cell neoplasms, standardized protocols are needed to increase the accuracy of diagnosis and classification and facilitate the implementation of automated MFC data analysis.
Keywords
- Type
- Chapter
- Information
- Publisher: Cambridge University PressPrint publication year: 2025
References
Alaggio, R, Amador, C, Anagnostopoulos, I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36: 1720–1748.CrossRefGoogle ScholarPubMed
Campo, E, Jaffe, ES, Cook, JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140: 1229–1253.CrossRefGoogle ScholarPubMed
Kroft, SH, Harrington, AM. How I diagnose mature T-cell proliferations by flow cytometry. Am J Clin Pathol 2022; 158: 456–471.CrossRefGoogle Scholar
Hill, AJ, Zhang, C, Kusakabe, M, et al. Occurrence of T-cell and NK-cell subsets with less well-recognized phenotypes in peripheral blood submitted for routine flow cytometry analysis. Cytometry B Clin Cytom 2021; 100: 235–239.CrossRefGoogle ScholarPubMed
Lima, M, Almeida, J, Teixeira, MA, et al. Reactive phenotypes after acute and chronic NK-cell activation. J Biol Regul Homeost Agents. 2004; 18: 331–334.Google ScholarPubMed
van Dongen, JJ, Langerak, AW, Brüggemann, M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia 2003; 17: 2257–2317.CrossRefGoogle ScholarPubMed
Langerak, AW, van Den Beemd, R, Wolvers-Tettero, IL, et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCR alpha beta T-cell proliferations. Blood 2001; 98: 165–173.CrossRefGoogle ScholarPubMed
Maciocia, PM, Wawrzyniecka, PA, Philip, B, et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017; 23: 1416–1423.CrossRefGoogle Scholar
Novikov, ND, Griffin, GK, Dudley, G, et al. Utility of a simple and robust flow cytometry assay for rapid clonality testing in mature peripheral T-cell lymphomas. Am J Clin Pathol 2019; 151: 494–503.CrossRefGoogle ScholarPubMed
Shi, M, Jevremovic, D, Otteson, GE, Timm, MM, Olteanu, H, Horna, P. Single antibody detection of T-cell receptor αβ clonality by flow cytometry rapidly identifies mature T-cell neoplasms and monotypic small CD8-positive subsets of uncertain significance. Cytometry B Clin Cytom 2020; 98: 99–107.CrossRefGoogle ScholarPubMed
Horna, P, Shi, M, Olteanu, H, Johansson, U. Emerging role of T-cell receptor constant β chain-1 (TRBC1) expression in the flow cytometric diagnosis of T-cell malignancies. Int J Mol Sci 2021; 22: 1817.CrossRefGoogle ScholarPubMed
Muñoz-García, N, Lima, M, Villamor, N, et al. Anti-TRBC1 antibody-based flow cytometric detection of T-cell clonality: standardization of sample preparation and diagnostic implementation. Cancers (Basel) 2021; 13: 4379.CrossRefGoogle ScholarPubMed
Matutes, E, Brito-Babapulle, V, Swansbury, J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991; 78: 3269–3274.CrossRefGoogle ScholarPubMed
Staber, PB, Herling, M, Bellido, M, et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood 2019; 134: 1132–1143.CrossRefGoogle ScholarPubMed
Chen, X, Cherian, S. Immunophenotypic characterization of T-cell prolymphocytic leukemia. Am J Clin Pathol 2013; 140: 727–735.CrossRefGoogle ScholarPubMed
Gilles, SR, Yohe, SL, Linden, MA, Dolan, M, Hirsch, B, Grzywacz, B. CD161 is expressed in a subset of T-cell prolymphocytic leukemia cases and is useful for disease follow-up. Am J Clin Pathol 2019; 152: 471–478.CrossRefGoogle Scholar
Herling, M, Patel, KA, Teitell, MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 2008; 111: 328–337.CrossRefGoogle ScholarPubMed
Thick, J, Metcalfe, JA, Mak, YF, et al. Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients. Oncogene 1996; 12: 379–386.Google ScholarPubMed
Brito-Babapulle, V, Catovsky, D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 1991; 55: 1–9.CrossRefGoogle ScholarPubMed
Wahnschaffe, L, Braun, T, Timonen, S, et al. JAK/STAT-activating genomic alterations are a hallmark of T-PLL. Cancers (Basel) 2019; 11: 1833.CrossRefGoogle ScholarPubMed
Uchiyama, T, Yodoi, J, Sagawa, K, Takatsuki, K, Uchino, H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 481–492.CrossRefGoogle ScholarPubMed
O’Donnell, S, Hunt, SK, Chappell, KH. Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma. Lancet Haematol 2023; 10: e539–e548.CrossRefGoogle ScholarPubMed
Shimoyama, M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79: 428–437.CrossRefGoogle Scholar
Karube, K, Ohshima, K, Tsuchiya, T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004; 126: 81–84.CrossRefGoogle ScholarPubMed
Shao, H, Yuan, CM, Xi, L, et al. Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma. Am J Clin Pathol 2010; 133: 592–601.CrossRefGoogle ScholarPubMed
Rowan, AG, Dillon, R, Witkover, A, et al. Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis. Blood 2020; 135: 2023–2032.CrossRefGoogle ScholarPubMed
Kataoka, K, Nagata, Y, Kitanaka, A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 2015; 47: 1304–1315.CrossRefGoogle ScholarPubMed
Vermeer, MH, Moins-Teisserenc, H, Bagot, M, Quaglino, P, Whittaker, S. Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardized approach. Br J Dermatol 2022; 187: 21–28.CrossRefGoogle ScholarPubMed
García-Díaz, N, Piris, MÁ, Ortiz-Romero, PL, Vaqué, JP. Mycosis Fungoides and Sézary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy. Cancers (Basel) 2021; 13: 1931.CrossRefGoogle ScholarPubMed
Olsen, EA, Whittaker, S, Willemze, R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022; 140: 419–437.CrossRefGoogle ScholarPubMed
Horna, P, Wang, SA, Wolniak, KL, et al. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics. Cytometry B Clin Cytom 2021; 100: 142–155.CrossRefGoogle ScholarPubMed
Pulitzer, MP, Horna, P, Almeida, J. Sézary syndrome and mycosis fungoides: an overview, including the role of immunophenotyping. Cytometry B Clin Cytom 2021; 100: 132–138.CrossRefGoogle ScholarPubMed
Illingworth, A, Johansson, U, Huang, S, et al. International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: assay development/optimization, validation, and ongoing quality monitors. Cytometry B Clin Cytom 2021; 100: 156–182.CrossRefGoogle ScholarPubMed
Boonk, SE, Zoutman, WH, Marie-Cardine, A, et al. Evaluation of immunophenotypic and molecular biomarkers for Sézary syndrome using standard operating procedures: a multicenter study of 59 patients. J Invest Dermatol 2016; 136: 1364–1372.CrossRefGoogle ScholarPubMed
Hristov, AC, Vonderheid, EC, Borowitz, MJ. Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome. Am J Clin Pathol 2011; 136: 944–953.CrossRefGoogle ScholarPubMed
Lewis, NE, Gao, Q, Petrova-Drus, K, et al. PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome. Cytometry B Clin Cytom 2022; 102: 189–198.CrossRefGoogle ScholarPubMed
Pileri, A, Tabanelli, V, Fuligni, F, et al. PD-1 and PD-L1 expression in mycosis fungoides and Sézary Syndrome. Ital J Dermatol Venerol 2022; 157: 355–362.Google ScholarPubMed
Xie, Y, Jaffe, ES. How I diagnose angioimmunoblastic T-cell lymphoma. Am J Clin Pathol 2021; 156: 1–14.CrossRefGoogle Scholar
Rodriguez-Sevilla, JJ, Ferrer, A, Colomo, L, Sánchez, B, Arenillas, L, Calvo, X. Dissecting the sCD3-CD4+ T-cell population: A valuable screening tool for angioimmunoblastic T-cell lymphoma. Cytometry B Clin Cytom 2022; 102: 171–174.CrossRefGoogle ScholarPubMed
Dorfman, DM, Shahsafaei, A. CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2011; 35: 76–83.CrossRefGoogle ScholarPubMed
Mihashi, Y, Kimura, S, Iwasaki, H, et al. Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers. Diagn Pathol 2021; 16: 101.CrossRefGoogle ScholarPubMed
Fukumoto, K, Nguyen, TB, Chiba, S, Sakata-Yanagimoto, M. Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. Cancer Sci 2018; 109: 490–496.CrossRefGoogle ScholarPubMed
Rodríguez, M, Alonso-Alonso, R, Tomás-Roca, L, et al. Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. Blood Adv 2021; 5: 5588–5598.CrossRefGoogle ScholarPubMed
Vega, F, Medeiros, LJ, Gaulard, P. Hepatosplenic and other gamma delta T-cell lymphomas. Am J Clin Pathol 2007; 127: 869–880.CrossRefGoogle Scholar
Morice, WG, Macon, WR, Dogan, A, Hanson, CA, Kurtin, PJ. NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis. Leukemia 2006; 20: 883–886.CrossRefGoogle ScholarPubMed
Moignet, A, Lamy, T. Latest advances in the diagnosis and treatment of large granular lymphocytic leukemia. Am Soc Clin Oncol Educ Book 2018; 38: 616–625.CrossRefGoogle ScholarPubMed
Cheon, H, Dziewulska, KH, Moosic, KB, et al. Advances in the diagnosis and treatment of large granular lymphocytic leukemia. Curr Hematol Malig Rep 2020; 15: 103–112.CrossRefGoogle ScholarPubMed
Barilà, G, Teramo, A, Calabretto, G, et al. Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. Leukemia 2020; 34: 1116–1124.CrossRefGoogle ScholarPubMed
Semenzato, G, Calabretto, G, Barilà, G, Gasparini, VR, Teramo, A, Zambello, R. Not all LGL leukemias are created equal. Blood Rev 2023; 60: 101058.CrossRefGoogle ScholarPubMed
Semenzato, G, Teramo, A, Calabretto, G, Gasparini, VR, Zambello, R. All that glitters is not LGL Leukemia. Leukemia 2022; 36: 2551–2557.CrossRefGoogle Scholar
Cheon, H, Xing, JC, Moosic, KB, et al. Genomic landscape of TCRαβ and TCRγδ T-large granular lymphocyte leukemia. Blood 2022; 139: 3058–3072.CrossRefGoogle ScholarPubMed
Olson, TL, Cheon, H, Xing, JC, et al. Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. Blood 2021; 138: 662–673.CrossRefGoogle ScholarPubMed
Baer, C, Kimura, S, Rana, MS, et al. CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk. Nat Genet 2022; 54: 637–648.CrossRefGoogle ScholarPubMed
Teramo, A, Binatti, A, Ciabatti, E, et al. Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation. Nat Commun 2022; 13: 3298.CrossRefGoogle ScholarPubMed
Barilà, G, Grassi, A, Cheon, H, et al. Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients. Blood 2023; 141: 1036–1046.CrossRefGoogle ScholarPubMed
Pastoret, C, Desmots, F, Drillet, G, et al. Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells. Blood 2021; 137: 3237–3250.CrossRefGoogle ScholarPubMed
Bárcena, P, Jara-Acevedo, M, Tabernero, MD, et al. Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality. Oncotarget 2015; 6: 42938–42951.CrossRefGoogle ScholarPubMed
Hussein, SE, Medeiros, LJ, Khoury, JD, et al. Agressive NK-cell leukemia: current state of the art. Cancers 2022; 12: 2900.CrossRefGoogle Scholar
Cogan, E, Schandené, L, Crusiaux, A, Cochaux, P, Velu, T, Goldman, M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994; 330: 535–538.CrossRefGoogle Scholar
Carpentier, C, Verbanck, S, Schandené, L, et al. Eosinophilia associated with CD3-CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients. Front Immunol 2020; 11: 1765.CrossRefGoogle ScholarPubMed
Umrau, K, Naganuma, K, Gao, Q, et al. Activating STAT5B mutations can cause both primary hypereosinophilia and lymphocyte-variant hypereosinophilia. Leuk Lymphoma 2023; 64: 238–241.CrossRefGoogle ScholarPubMed
Shi, M, Olteanu, H, Jevremovic, D, et al. T-cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell large granular lymphocytic leukemia: implications for laboratory diagnostics. Mod Pathol 2020; 33: 2046–2057.CrossRefGoogle ScholarPubMed